Form 4: Corcept Therapeutics Officer Lyon Exercises Options and Sells Shares
SEC Form 4
Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on March 31 and April 1, 2025, according to a Form 4 filing.
Summary
- Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics, engaged in multiple transactions involving the company's stock on March 31 and April 1, 2025.
- Lyon exercised stock options to acquire a total of 200,650 shares of common stock at prices ranging from $13.56 to $19.26.
- Concurrently, Lyon sold 162,008 shares at a weighted average price of $100.2208, 32,942 shares at a weighted average price of $101.3726, 5,050 shares at a weighted average price of $102.4798, and 650 shares at a weighted average price of $114.5277.
- These sales were executed under a pre-arranged 10b5-1 trading plan adopted on August 30, 2024.
- Following these transactions, Lyon directly owns 9,009 shares of common stock and holds options to purchase 162,492 additional shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like the 10b5-1 plan, to manage personal finances.
Stakeholder Impact
- The transactions could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the trading plan and the relatively small volume compared to the overall market capitalization of the company.
Key Dates
| Date | Description |
|---|---|
| 08/30/2024 | Date of adoption of 10b5-1 trading plan |
| 06/03/2024 | Date of grant of restricted stock awards |
| 09/03/2024 | Date of grant of restricted stock awards |
| 12/02/2024 | Date of grant of restricted stock awards |
| 03/03/2025 | Date of grant of restricted stock awards |
| 03/31/2025 | Date of stock option exercises and sales |
| 04/01/2025 | Date of stock option exercises and sales |
| 04/02/2025 | Date of Form 4 filing |
| 02/07/2030 | Expiration date of some stock options |
| 07/13/2030 | Expiration date of some stock options |
| 02/02/2032 | Expiration date of some stock options |
Keywords
Form 4, insider trading, stock options, stock sale, CORT, Corcept Therapeutics, Lyon, Joseph Douglas Lyon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.